Abstract: The current study established that treatment of diabetes using compound 1(2,4-dinitroanilino-benzoic acid), an anthranilic acid derivative, by restoring the functional activities of the pancreas via its insulinotropic action.

Abstract: Novel ?-Glucosidase inhibitors include propanone substituted indole ring-containing heterocyclic compounds, which are represented by Formula I: Wherein R1 is thiophene, 2,4-di chloro phenyl, 2,6-di chloro phenyl, bromo phenyl, benzyl or nitrophenyl; and R2 is an aryl group, or stereoisomers or pharmaceutically acceptable salts thereof.

Abstract: The present invention is a development of a morphine plus buspirone combination (7.5 mg/kg morphine plus 1-2 mg/kg buspirone) used as a non-addictive treatment for killing severe pain. This combination is more effective than morphine alone for the treatment of pain and is more than 90% less addictive.

Abstract: This invention provides that Ropinirole (4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one) possess potent urease inhibitory potential (in vitro) with 97.3% inhibition and IC50=11.7+0.46 ?M, when compared to the standard inhibitors i.e. acetohydroxamic acid (IC50=41.5+1.50 ?M), and thiourea (IC50=21.0+0.50 ?M).

Abstract: The present invention relates to anti-thymidine phosphorylase compounds. These compounds are derivatives of 4-hydroxybenzohydarzide or generally Schiff bases of hydrazones. The invention evaluates a series of Schiff bases of hydrazones against thymidine phosphorylase, and identified significant inhibitors of thymidine phosphorylase enzyme during in vitro studies.

Abstract: This invention provides that (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid (captopril) possess potent in vitro urease inhibitory potential with 95.00% inhibition and IC50=16.6±1.52 ?M, when compared to the standard inhibitor i.e. acetohydroxamic acid (IC50=41.5±1.50 ?M).

Abstract: Novel ?-Glucosidase inhibitors include propanone substituted indole ring-containing heterocyclic compounds, which are represented by Formula I: Wherein R1 is thiophene, 2,4-di chloro phenyl, 2,6-di chloro phenyl, bromo phenyl, benzyl or nitrophenyl; and R2 is an aryl group, or stereoisomers or pharmaceutically acceptable salts thereof.

Abstract: Inhibitors of carbonic anhydrase-II derived from sulfanilamide are reported.

Abstract: The invention relates to a method of identifying inhibitors against target receptor ?-glucoronidase. Three compounds were found to be completely non-cytotoxic while, the remaining compounds showed moderate cytotoxicity.

Abstract: The diethylammonium salts of phenyl-substituted thiobarbituric acid as anti-diabetic agents include compounds having the formula: wherein X is: and wherein R1 is selected from the group consisting of a hydrogen, halogen, methyl, trifluoromethyl, methoxy, and nitro, and R2 is either halogen or hydrogen, the R1 and R2 substituents being independently bonded to an ortho-, meta-, or para-carbon of the phenyl substituent.

Abstract: One embodiment of the invention relates to treating diseases associated with increased urease enzyme activity comprising administering an effective amount of a compound selected from a group consisting of 28 thiazoles Schiff bases. Kinetic studies were performed on ten (10) of the most active compounds.

Abstract: Two thiourea derivatives N-(3-chlorophenyl)-N?-(3,4-difluorophenyl)thiourea and N-(3-chlorophenyl)-N-(3-methoxyphenyl)-thiourea are reported as treatment of multidrug resistance infections from Staphylococcus aureus.

Abstract: The invention relates to methods of inhibiting the protein glycation process and the associated formation of Advanced Glycation End products (AGEs) in hyperglycemia by administering 6-Nitrobenzimidazole derivatives. These derivatives were found to be effective not merely against the formation of AGE, but they can inhibit the action of AGEs at post-receptor levels.

Abstract: Anthranilic acid derivatives are used to inhibit the formation of advanced glycation end products to reduce complications in diabetes.

Abstract: One embodiment of the invention relates to treating diseases associated with increased urease enzyme activity comprising administering an effective amount of a compound selected from a group consisting of 28 thiazoles Schiff bases. Kinetic studies were performed on ten (10) of the most active compounds.

Abstract: Two thiourea derivatives N-(3-chlorophenyl)-N?-(3,4-difluorophenyl) thiourea and N-(3-chlorophenyl)-N-(3-methoxyphenyl)-thiourea are reported as treatment of multidrug resistance infections from Staphylococcus aureus.

Abstract: This invention provides new therapeutic potential of nandrolone or a derivative thereof, against protozoal diseases. More specifically, nandrolone or a derivative thereof exhibits anti-protozoal activity against Leishmania major. Anti-protozoal potential of nandrolone derivatives, such as compounds 1-8, can contribute in the development of effective therapies against protozoal diseases, such as leishmaniasis, trypanosomiasis, malaria, toxoplasmosis, babeosis, amoebic dysentery and lambliasis. Another aspect of the invention is a method of testing derivatives of nandrolone for anti-protozoal activity comprising growing Leishmania in the presence of the test derivative and determining the IC50 value.

Abstract: ?-Chymotrypsin inhibitors of thiourea class are reported that could be potent inhibitors of proteases, elastases, proteasomes, NS3 and NS4 serine protease of hepatitis C virus, dengue virus, etc. Compounds 1-22, which are belong to thiourea class, showed good inhibition. Their kinetics study and cytotoxicity profiles showed all type of inhibition except uncompetitive-type inhibition and no cytotoxicity except few compounds. Competitive type of inhibitors could inhibit other ?-chymotrypsin-like serine proteases, which are therapeutics target.

Abstract: Anthranilic acid derivatives are used to inhibit the formation of advanced glycation end products to reduce complications in diabetes.

Abstract: This invention provides a series of new oxindole derivatives 1-21, evaluated for their antiglycation potential by using in vitro BSA-MG glycation model. These derivatives showed a varying degree of antiglycation activity with IC50 values ranging between 150-856 ?M. Compound 14 (IC50=150.4±2.5 ?M) was found to be the most potent among all derivatives, even better than the standard inhibitor i.e. rutin (IC50=294.5±1.50 followed by compounds 13 and 8 with IC50 value of 194.40±2.5 and 211.41±4.1 ?M, respectively.